Avadel Pharmaceuticals plc (AVDL) Reaches $10.51 After 6.00% Up Move; Clementia Pharmaceuticals (CMTA) Shorts Up By 3.95%

January 14, 2018 - By Peter Erickson

The stock of Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a huge mover today! The stock increased 7.46% or $0.73 during the last trading session, reaching $10.51. About 631,800 shares traded or 123.55% up from the average. Avadel Pharmaceuticals plc (NASDAQ:AVDL) has risen 3.59% since January 14, 2017 and is uptrending. It has underperformed by 13.11% the S&P500.The move comes after 6 months positive chart setup for the $417.90M company. It was reported on Jan, 14 by Barchart.com. We have $11.14 PT which if reached, will make NASDAQ:AVDL worth $25.07M more.

Clementia Pharmaceuticals Incorporated (NASDAQ:CMTA) had an increase of 3.95% in short interest. CMTA’s SI was 152,600 shares in January as released by FINRA. Its up 3.95% from 146,800 shares previously. With 38,800 avg volume, 4 days are for Clementia Pharmaceuticals Incorporated (NASDAQ:CMTA)’s short sellers to cover CMTA’s short positions. The stock increased 1.21% or $0.2 during the last trading session, reaching $16.73. About 19,449 shares traded. Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. The company has market cap of $530.64 million. The Company’s lead product candidate is palovarotene, an oral small molecule that binds and activates retinoic acid receptor gamma, and prevents abnormal new bone formation, as well as scar tissue formation in various tissues in animal models. It currently has negative earnings. The firm is developing palovarotene for the treatment of fibrodysplasia ossificans progressiva and multiple osteochondroma, as well as has one Phase III and Phase II/III trials for two separate indications.

Avadel Pharmaceuticals PLC identifies, develops, and commercializes pharmaceutical products for primary care and sterile injectable markets in the United States, France, and Ireland. The company has market cap of $417.90 million. The companyÂ’s owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-deterrent modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. It has a 5.42 P/E ratio. The Company’s lead products include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection used to treat hypotension; and Akovaz, an ephedrine sulfate injection.

Analysts await Avadel Pharmaceuticals plc (NASDAQ:AVDL) to report earnings on March, 6. After $0.09 actual earnings per share reported by Avadel Pharmaceuticals plc for the previous quarter, Wall Street now forecasts -400.00% negative EPS growth.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>